Procter & Gamble Hygiene and Health Care Limited (PGHH) Fair Value & Analysis
Consumer Defensive · IN · Market cap ₹289B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price −4.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹8,813 – ₹14,147 · fair‑value band ₹3,661 – ₹6,037 · the ₹8,902 price screens above the ₹4,865 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Procter & Gamble Hygiene and Health Care Limited (PGHH) currently trades at ₹8,902, while our model-based Fair Value estimate is ₹4,865 — implying the stock looks roughly 45.4% overvalued today. We read business quality at 66/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Procter & Gamble Hygiene and Health Care Limited generated revenue of ₹42.9B at a net margin of 20.0%. Revenue declined 5.1% year over year. It earns a return on equity of 114.9%. The balance sheet holds a net cash position of ₹5.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Health care Products and Hygiene Products segments. The company offers health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads. It also provides baby care products comprising nappies, pants, and baby wipes; grooming products; laundry products; hair care products; home, personal and skin care, and oral products. The company sells its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brands through mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was incorporated in 1964 and is …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Procter & Gamble Hygiene and Health Care Limited reported revenue of ₹42.8B in FY2026 versus ₹37.9B in FY2022, a compound +3.1%/yr. Reported net income was ₹8.6B in FY2026, compounding +10.4%/yr from FY2022.
Is PGHH fairly valued? → Check now
Similar stocks
6 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | 2,590 MXN | 1,732 MXN | -33% |
| L'Oréal S.A LRLCF | $450.56 | $209.17 | -54% |
| Unilever PLC UNLYF | $59.34 | $46.11 | -22% |
| Colgate-Palmolive Company CPA | €79.98 | €55.96 | -30% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,170 | ₹807.38 | -63% |
| Reckitt Benckiser Group RBGLY | $12.32 | $17.37 | +41% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Procter & Gamble Hygiene and Health Care Limited (PGHH) undervalued?
What is the fair value of PGHH?
What is the quality score of PGHH?
What is the revenue of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
What is the net profit margin of PGHH?
Does Procter & Gamble Hygiene and Health Care Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.